Extracellular Vesicles for Tissue Repair: Scientific Review and Clinical Perspectives

Abstract

Extracellular vesicles (EVs), including exosomes and microvesicles, have emerged as pivotal mediators of intercellular communication with substantial implications for tissue repair and regeneration. This review synthesizes current evidence on the biological functions, therapeutic mechanisms, and clinical relevance of EVs in tissue repair, highlighting recent advances, risk factors, diagnostic perspectives, and guideline-based recommendations to inform medical professionals about their evolving role in regenerative medicine.

Introduction

Tissue injury and the subsequent repair process are central themes in medicine, spanning acute trauma to chronic degenerative diseases. Traditional therapeutic modalities often fall short in restoring full tissue integrity or function. The discovery of extracellular vesicles (EVs) as carriers of bioactive molecules has introduced a paradigm shift, with mounting evidence supporting their role as modulators of tissue repair. This review aims to provide clinicians and researchers with a comprehensive understanding of EV biology, their application in tissue repair, and the ongoing translational challenges and opportunities.

Epidemiology / Disease Burden

Tissue injuries account for a significant proportion of global morbidity and healthcare expenditure, with musculoskeletal injuries, cardiovascular events, and chronic wounds being particularly prevalent. According to global estimates, over 310 million major surgical procedures are performed annually, many of which involve tissue repair. Chronic non-healing wounds affect approximately 1-2% of the population in developed countries, while cardiovascular tissue damage remains a leading cause of mortality worldwide. The burden is further amplified by aging demographics and the increasing prevalence of diabetes and vascular diseases, highlighting an urgent need for novel regenerative strategies such as EV-based therapeutics.

Pathophysiology

EVs are membrane-bound particles released by cells under physiological and pathological conditions, encompassing exosomes (30–150 nm), microvesicles (100–1000 nm), and apoptotic bodies. They encapsulate proteins, lipids, mRNAs, microRNAs, and other non-coding RNAs, facilitating horizontal transfer of molecular information. In tissue repair, EVs derived from mesenchymal stem cells (MSCs), endothelial cells, and immune cells modulate key processes such as inflammation, angiogenesis, extracellular matrix remodeling, and cellular proliferation. EVs can deliver growth factors, anti-inflammatory mediators, and nucleic acids to recipient cells, thereby orchestrating a favorable microenvironment for regeneration. Dysregulation of EV release or content may contribute to impaired healing or fibrosis.

Risk Factors

Factors influencing the efficacy and safety of EV-mediated tissue repair include the source and condition of donor cells, methods of EV isolation and purification, and patient-specific variables such as age, comorbidities, and immunological status. Underlying conditions such as diabetes, vascular insufficiency, chronic inflammation, and advanced age may alter EV biogenesis, cargo composition, and the recipient tissue\'s responsiveness. Additionally, improper characterization or contamination with unwanted particles during EV preparation poses risks of immune reactions or off-target effects, underscoring the need for stringent quality control in clinical applications.

Clinical Features

Clinically, impaired tissue repair manifests as delayed wound healing, persistent inflammation, scar formation, or compromised organ function. In preclinical and early-phase clinical studies, EV-based therapies have shown promise in accelerating wound closure, enhancing cardiac function post-myocardial infarction, promoting nerve regeneration, and reducing fibrosis. Features observed include improved angiogenesis, reduced inflammatory infiltrates, and enhanced structural and functional restoration of injured tissues. Monitoring these clinical endpoints is essential for evaluating therapeutic efficacy and safety in ongoing trials.

Diagnosis

The assessment of tissue repair typically relies on clinical evaluation, imaging modalities, and histological analysis. Emerging diagnostic strategies now incorporate the profiling of circulating EVs as biomarkers of tissue injury, repair capacity, and therapeutic response. Quantitative and qualitative analysis of EVs using nanoparticle tracking analysis, flow cytometry, and next-generation sequencing enables non-invasive monitoring of disease progression and treatment outcomes. The diagnostic utility of EVs is an area of active research, with potential to guide patient selection and optimization of EV-based interventions.

Treatment & Management

Current approaches to tissue repair include surgical interventions, pharmacotherapies, and biologics such as growth factors and stem cell therapies. EV-based therapeutics are being developed as cell-free alternatives, leveraging their ability to recapitulate many of the paracrine effects of stem cells without associated risks such as tumorigenicity or immune rejection. Administration routes under investigation include local injection, topical application, and intravenous infusion. Challenges in standardizing dose, delivery methods, and ensuring scalability remain to be addressed before widespread clinical adoption. Adjunctive use of EVs with established therapies may further enhance repair outcomes.

Recent Advances / Emerging Therapies

Recent advances in EV research include the engineering of designer EVs with enhanced targeting, loading of therapeutic RNAs or proteins, and modification of surface markers to improve biodistribution. Clinical trials are evaluating allogeneic and autologous EVs for indications such as chronic wounds, myocardial infarction, and osteoarthritis. Innovations in large-scale EV production, purification, and characterization are facilitating the translation of EV-based products to clinical-grade therapeutics. Preclinical studies demonstrate that EVs can be combined with biomaterials or scaffolds to provide sustained release and synergistic effects in tissue engineering applications.

Guideline Recommendations

While formal clinical practice guidelines for EV-based therapies are still under development, regulatory agencies such as the FDA and EMA emphasize the need for rigorous characterization, potency assays, and safety testing. Consensus statements from scientific societies recommend standardized protocols for EV isolation, quantification, and functional assessment. Ongoing multicenter trials and registries will inform future guideline updates, with a focus on patient selection, indications, dosing regimens, and monitoring for adverse effects.

Conclusion

Extracellular vesicles represent a transformative frontier in regenerative medicine, offering novel mechanisms and practical solutions for tissue repair. Their ability to modulate inflammation, promote angiogenesis, and deliver reparative signals positions them as promising candidates for cell-free therapies. Continued research into EV biology, standardization of production processes, and robust clinical trials are essential to unlock their full potential and integrate them into mainstream medical practice. As the field evolves, EV-based therapeutics may redefine the landscape of tissue repair and regenerative interventions for a broad spectrum of clinical conditions.